Far Infrared Radiation Treatment of Dementia and Other Mental Illness
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Dementia and Other Related Mental Illness.|
- The primary end point is to determine the therapeutic effects of far infrared radiation on dementia. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other related mental illness including Alzheimer's, multiple sclerosis and stroke rehabilitation. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||February 2008|
|Estimated Study Completion Date:||March 2009|
|Estimated Primary Completion Date:||January 2009 (Final data collection date for primary outcome measure)|
Radiation: Far Infrared
Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
Dementia is the progressive decline in cognitive function due to damage or disease in the brain beyond what might be expected from normal aging. Particularly affected areas include memory, attention, language, and problem solving. Especially in the later stages of the condition, affected persons may be disoriented in place and in person (not knowing who they are).
The prevalence of dementia is rising as the global life expectancy is rising. Particularly in Western countries, there is increasing concern about the economic impact that dementia will have in future, older populaces.
It is a disease that is strongly associated with age; 1% of those aged 60-65, 6% of those aged 75-79, and 45% of those aged 95 or older suffer from the disease.
We are postulating that the use of far infrared radiation on the central nervous system, the endocrine system and the viscera will have a positive effect on treating dementia and other neurological illnesses.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00574054
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Principal Investigator:||Kwasi Donyina, Ph.D.||GAAD Medical Research Institute Inc.|
|Study Director:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|